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Sleep apnea/hypopnea disorders include centrally originated diseases and obstructive
sleep apnea (OSA). This last condition is renowned as a frequent secondary cause
of hypertension (HT). The mechanisms involved in the pathogenesis of HT can be
summarized in relation to two main pathways: sympathetic nervous system stimulation
mediated mainly by activation of carotid body (CB) chemoreflexes and/or asphyxia, and,
by no means the least important, the systemic effects of chronic intermittent hypoxia
(CIH). The use of animal models has revealed that CIH is the critical stimulus underlying
sympathetic activity and hypertension, and that this effect requires the presence of
functional arterial chemoreceptors, which are hyperactive in CIH. These models of CIH
mimic the HT observed in humans and allow the study of CIH independently without
the mechanical obstruction component. The effect of continuous positive airway pressure
(CPAP), the gold standard treatment for OSA patients, to reduce blood pressure seems
to be modest and concomitant antihypertensive therapy is still required. We focus this
review on the efficacy of pharmacological interventions to revert HT associated with CIH
conditions in both animal models and humans. First, we explore the experimental animal
models, developed to mimic HT related to CIH, which have been used to investigate
the effect of antihypertensive drugs (AHDs). Second, we review what is known about
drug efficacy to reverse HT induced by CIH in animals. Moreover, findings in humans
with OSA are cited to demonstrate the lack of strong evidence for the establishment
of a first-line antihypertensive regimen for these patients. Indeed, specific therapeutic
guidelines for the pharmacological treatment of HT in these patients are still lacking.
Finally, we discuss the future perspectives concerning the non-pharmacological and
pharmacological management of this particular type of HT.
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CHRONIC INTERMITTENT HYPOXIA-RELATED DISORDERS
Is is well established that intermittent hypoxia (IH) affects control
of breathing, the autonomic nervous system and the cardiovas-
cular system (Foster et al., 2007). Chronic intermittent hypoxia
(CIH) is a feature that is present in interstitial lung disease
(Fletcher et al., 1992a) and sleep-disordered breathing (SDB), and
it has also been shown to occur in patients with hepatopulmonary
syndrome (Tanné et al., 2005; Ogata et al., 2006; Palma et al.,
2008). Since several years ago, there has been growing interest
concerning CIH due to the high relevance of the part assumed to
be played by sleep-related breathing disorders in chronic diseases.
Sleep apnea/hypopnea disorders include centrally originated
diseases and obstructive sleep apnea (OSA). Central sleep apnea
(CSA) is characterized by a lack of drive to breathe during
sleep, resulting in insufficient or absent ventilation and compro-
mised gas exchange (Eckert et al., 2007). In CSA, the cessation
of respiration during sleep is not associated with ventilatory
effort and there is sleep fragmentation due to arousals associ-
ated with reflexes activated by the ensuing hypoxemia (Paiva and
Attarian, 2014). The major manifestations of CSA include high
altitude-induced periodic breathing, idiopathic CSA, narcotic-
induced central apnea, obesity hypoventilation syndrome, and
Cheyne-Stokes breathing in heart failure (Eckert et al., 2007).
While the precipitating mechanisms involved in the several types
of CSA may diverge, unstable ventilatory drive during sleep is
the principal underlying feature (Eckert et al., 2007). CSA is
diagnosed in approximately 5% of the patients who undergo a
polysomnographic study (Khan and Franco, 2014). On the other
hand, OSA is briefly characterized by repetitive episodes of airflow
cessation (apnea) or airflow reduction (hypopnea) caused by an
obstructed or collapsed upper airway during sleep. Unlike CSA,
obstruction occurs in OSA despite the central drive to breathe
and inspiratory muscle activity (Levitzky, 2008). An apprecia-
ble number of factors are known to be linked to upper-airway
collapse, namely reduced airway dilator muscle activity during
sleep, upper-airway anatomy, obesity, decreased end-expiratory
lung volume, ventilatory control instability, and rostral fluid shifts
(Kapur, 2010). The repetitive episodes of apnea and hypopnea
characteristic of OSA are closely associated with CIH, hypercap-
nia and an increase in intrathoracic pressure, leading to recurrent
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arousals and significant changes in sleep architecture. OSA is
affecting a growing proportion of the common population, and
the estimated prevalence in the 1990s was 9% for women and 24%
for men among middle-aged adults (Young et al., 1993). In addi-
tion, CSA can occur concomitantly with OSA. This last condition,
recently labeled complex sleep syndrome, is observed in approxi-
mately 15% of the patients following treatment with continuous
positive airway pressure (CPAP) (Paiva and Attarian, 2014). In a
few words, complex sleep syndrome is a form of SDB in which
CSA persists or emerges when obstructive events have disap-
peared using a positive pressure device (Khan and Franco, 2014).
In clinical practice, when a few central apneas are observed in
polysomnograms of patients with OSA, they are normally ignored
because we do not presently understand their potencial clinical
relevance.
Nowadays, it is well known that the outcomes of these sleep-
related breathing disorders can lead to vascular diseases, con-
tributing to a considerable increase in overall cardiovascular risk.
The desaturation-reoxygenation sequence, a typical pattern cou-
pled with the majority of respiratory events, is thought to be
responsible for most of the associated cardiovascular morbid-
ity (Lévy et al., 2012). Although OSA has been associated with
several cardiovascular conditions, it has been more closely etio-
logically connected to systemic HT (Kapa et al., 2008), and the
link between HT and OSA is now widely accepted and supported
by different findings.Most episodes of OSA are coupled with sleep
disruption, which per se increases sympathetic nerve activity and
blood pressure (Morgan et al., 1996). In addition, the occurrence
of arousals appears to enhance the pressor effects of asphyxia dur-
ing OSA (Morgan et al., 1998), contributing synergistically to
blood pressure increase. In any case, studies in both animals and
humans underline the major role of hypoxia itself in promoting
an increase in blood pressure (Brooks et al., 1997b; Tamisier et al.,
2011).
Regarding CSA, this SDB, like OSA, is strongly linked to car-
diac disease and cardiovascular outcomes (Brenner et al., 2008).
Indeed, the majority of patients with CSA have underlying car-
diovascular disease, primarily heart failure, which is considered
the most common risk factor for CSA, followed by atrial fibril-
lation (Bradley and Phillipson, 1992). Moreover, like OSA, CSA
has been implicated in heart failure pathophysiology (Mehra,
2014) and occurs in 30–50% of patients with left ventricular dys-
function and heart failure caused by HT, cardiomyopathy and
ischemic heart disease (Bradley and Floras, 2003). Thus, CSA
has significant co-morbidity withmany cardiac conditions, which
clearly contributes to an increase in the associated mortality and
morbidity.
Besides systemic HT, chronic intermittent alveolar and sys-
temic arterial hypoxia-hypercapnia can cause pulmonary HT
(PH). SDB has also been found to be associated with PH, being
considered one of the potential etiologies of PH (Galie et al.,
2009). During episodes of OSA, the subsequent oscillations in
PaO2 lead to a cyclical pattern of vasoconstrictions and relax-
ations in the pulmonary circulation responsible for the marked
fluctuations observed in pulmonary arterial pressure (Dempsey
et al., 2010). The perpetuation of this pattern leads to fixed ele-
vations in pulmonary pressure (Dempsey et al., 2010). Some
data suggest that even slight changes in pulmonary function, in
the absence of lung disease, are able to induce PH in patients
with OSA. Furthermore, it is important to bear in mind that
PH could also be a cause of abnormal arterial blood gases dur-
ing wakefulness (Dempsey et al., 2010) and that OSA itself
can lead to PH (Sajkov and McEvoy, 2009). The major conse-
quence of the increased pulmonary artery pressure, together with
increased blood viscosity (a consequence of the renal release of
erythropoietin subsequent to hypoxemia), is the occurrence of
right ventricle hypertrophy leading to cor pulmonale (Levitzky,
2008). The prevalence of this chronic cardiopulmonary condition
among patients with SDB is estimated to range from 17 to 52%
(Minic et al., 2014), and 20–30% of untreated OSA patients suf-
fer from PH (Dumitrascu et al., 2013). Even if PH in this group of
patients is typically not severe (Badesch et al., 2010), OSA patients
with PH have a higher mortality rate than OSA patients without
PH (Minai et al., 2009). A recent meta-analysis shows that CPAP
is associated with a mild but statistically significant reduction in
pulmonary artery pressure in OSA patients (Sun et al., 2014). This
decreasemight translate into a better outcome in patients with PH
secondary to OSA. However, more studies are needed to confirm
this assumption.
Taking into account its high prevalence and its associated
adverse impact on cardiovascular, metabolic and other health
outcomes, this review focuses on OSA and systemic HT.
OSA AND HT: HOW RELEVANT IS THIS LINKAGE?
Since 2003, OSA has formally been recognized as a frequent
and important secondary cause of HT and is one of the first
causes to be screened mainly in patients with a suggestive pheno-
type, refractory HT and a non-dipping profile (Chobanian et al.,
2003; Mancia et al., 2007). More recently, OSA has been iden-
tified as an independent risk factor for HT (Lavie et al., 2000;
Peppard et al., 2000; Marin et al., 2012), as one of the major clin-
ical conditions that favors poorly controlled HT (Oliveras and
Schmieder, 2013), and as the most common condition associ-
ated with resistant HT (Pedrosa et al., 2011). OSA and HT are
two prevailing risk factors for several cardiovascular events (Wang
and Vasan, 2005; Baguet et al., 2009). Due to their high preva-
lence and cardiovascular morbidity (Wolf et al., 2007; Malhotra
and Loscalzo, 2009), OSA and HT are now acknowledged as
public health problems. Epidemiological data show that the esti-
mated overall prevalence of HT among patients with OSA is
approximately 50% and an estimated 30–40% of hypertensive
patients are diagnosed with OSA (Calhoun, 2010), confirming
the bidirectional relationship between OSA and HT. Moreover,
OSA and HT are chronic diseases mostly diagnosed in active
adults and because of the associations between OSA and obe-
sity and advancing age, the public health burden of OSA related
to cardiovascular disease is expected to rise in the coming years
(Dempsey et al., 2010). The use of both antihypertensive drugs
(AHDs) and CPAP in these patients is for life and consequently
treatment is associated with a high impact both in terms of costs
and in patients’ quality of life. Indeed, OSA generates an impres-
sive economic burden, including medical costs, when compared
to other equally relevant chronic diseases (Kapur, 2010; Badran
et al., 2014).
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OSA AND HT: WHAT IS THE PROBLEM?
CPAP is considered the gold standard treatment for mild, mod-
erate and severe OSA due to its remarkable ability in providing
pneumatic splitting of the upper airway and effectiveness in
reducing the apnea-hypopnea index (AHI), symptoms, and car-
diovascular morbidity and mortality (Hla et al., 2002; Pepperell
et al., 2002; Wolf et al., 2007; Epstein et al., 2009; Mannarino
et al., 2012). Besides preventing hypoxemia, sleep disturbance
and apnea episodes, CPAP reduces sympathetic activity, systemic
inflammation and oxidative stress (Yorgun et al., 2014). However,
the results found for the effectiveness of CPAP on blood pres-
sure (BP) control are still controversial. Table 1 summarizes the
results of original studies in which the effect of CPAP on BP has
been analyzed. Whereas some studies and meta-analyses (Bakker
et al., 2014; Varounis et al., 2014) have reported modest effects for
CPAP in lowering BP, others tend to support the beneficial effect
of CPAP treatment on BP reduction and attenuating the risk of
developing HT. In any case, although the lowering effect of CPAP
on BP is relevant in terms of overall cardiovascular risk reduction,
this effect is very limited when compared to the performance of
AHDs in patients with essential HT (Pépin et al., 2009). Thus,
treating HT in patients with sleep apnea is proving to be a difficult
task and there is consensus that the use of AHDs is mandatory. In
spite of this, data on AHDs regimens in patients with OSA are
scarce and there is a lack of specific therapeutic guidelines for the
pharmacological treatment of HT in these patients. Furthermore,
the effects of AH agents onOSA patients are not consistent (Parati
et al., 2012) and there are no data on the efficacy of specific AHDs
regimens when associated with CPAP.
A new treatment for OSA patients is the oral appli-
ance/mandibular advancement device (Guralnick and Bakris,
2012). Oral appliance therapy is an important alternative to CPAP
for some patients with mild to moderate OSA (Iftikhar et al.,
2013). Despite a recent study (Andrén et al., 2013) and a recent
meta-analysis (Iftikhar et al., 2013) which have shown some
beneficial effects of this device in reducing blood pressure mea-
surements, larger and longer randomized control trials are needed
to confirm the effects of oral appliance therapy on BP control.
Clearly, more studies are required to identify first-line AHDs
regimens for optimal BP control in this particular group of
hypertensive patients (Tsioufis et al., 2010; Parati et al., 2013).
Moreover, HT related to OSA needs to be managed as a specific
entity and an earlier diagnosis of this type of HT seems to be as
relevant as the selection of AHDs regimens. This work provides,
for the first time, a systematic review on the efficacy of AHDs in
HT related to OSA.
WHAT MODELS ARE AVAILABLE TO STUDY HT RELATED TO
OSA?
Due to the high complexity and heterogeneity associated with
OSA, considerable variability can be observed between reports
addressed at the study of this disease. In addition, the scarcity of
opportunities for patient investigation, in particular at the cellular
level, has compromised progress in understanding the patho-
physiology of OSA and the development of novel and specific
treatments for this disorder. To overcome some of these limita-
tions, several animal models and more recently, a model of OSA
in healthy human volunteers (Tamisier et al., 2009, 2011) have
been developed. Animal models, especially of IH, mimic OSA
more easily than human models. The small size of rodents allows
more rapid and intense changes in SaO2 whereas humans require
longer periods of hypoxia to induce arterial oxyhaemoglobin
desaturation (Foster et al., 2007). The combination of these two
approaches is certain to contribute to the consolidation of preven-
tion strategies and the development of more suitable treatments
for OSA patients.
ANIMAL MODELS
The major advantage of the use of animal models is that they
allow single components of the disease to be evaluated, accu-
rately controlling the triggering events in terms of both severity
and duration, and providing homogeneous populations (Lévy
et al., 2012). These models also provide an excellent opportunity
to explore the underlying mechanistic pathways of HT related
to OSA and their consequences under controlled conditions.
Moreover, animal models have enabled the study of parameters
that have proved difficult to assess in humans, particularly due to
the need for organ harvesting to explore the mechanisms under-
lying the consequences of IH at the molecular level (Dematteis
et al., 2009). Thus, studies with animal models are good tools for
overcoming some confounding factors present in human studies
(e.g., the presence of comorbidities, disease duration, and behav-
ioral and environmental variables) (Badran et al., 2014), and for
providing more specific information concerning the efficacy of
drugs to be tested.
In 2009, Dematteis et al. used the terminology homologous
(sharing the cause or pathophysiology of the human disease),
predictive (responding to treatment similarly to the human dis-
ease) and isomorphic (displaying symptoms similar to those of
the human disease although their cause and pathophysiology may
differ) to categorize sleep apnea models (Dematteis et al., 2009).
According to these categories, most sleep apnea models are only
partially isomorphic, focusing on a specific aspect of the human
disease. As a matter of fact, none of the currently available ani-
mal models reproduce all aspects of human sleep apnea and
they present some important limitations. Nonetheless, the ani-
mal models of sleep apnea have brought out most of the available
knowledge in this field and furthermore, almost all cardiovascu-
lar diseases known to be present in patients with OSA have been
replicated in these models (Dumitrascu et al., 2013).
The effective use of animals to study sleep apnea implies
recognition of the natural similarities and differences between
animals and humans to ensure the reliability of the experimen-
tal results. For instance, as rodents are nocturnal animals, the
stimulus must be applied during the sleep-dominant phase of
the diurnal cycle. Moreover, in humans the circadian distribu-
tion of sleep tends to be consolidated and normally monophasic,
with a daily sleep duration of 7–8 h, whereas it is polyphasic,
relatively fragmented and with a duration of 12–15 h in rodents
(Toth and Bhargava, 2013). Another issue is related to the fact
that rodents sleep in the prone position (Golbidi et al., 2012);
it is well known that supine OSA is the dominant phenotype
of OSA syndrome and that the supine position favors upper
airway collapse in humans (Joosten et al., 2014). Furthermore,
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Table 1 | CPAP effect on blood pressure.
Study design n Study
duration
HT patients (%) AHDs (Y/N) Mean CPAP use
(h/night)
BP outcome References
RCT; parallel group;
blinded endpoint
194 12 weeks 100 Yes 5 ↓ 3.1mmHg MBP
↓ 3.2mmHg DBP
↓ 3.1mmHg SBP (NS)
Martínez-García
et al., 2013
RCT; parallel group 118 4 weeks 10 Yes 4.9 ↓ 3.3mmHg 24h MBP Pepperell et al.,
2002
Case -controlled
study
48 4 weeks 79 Yes 5.1 ↓ 5.2mmHg DBP
↓ 3.8mmHg SBP (NS)
Zhao et al., 2012
Prospective
randomized trial
32 9 weeks 66 Yes 5.5 ↓ ± 10mmHg MBP
↓ ± 10mmHg DBP
↓ ± 10mmHg SBP
(During both day and
night-time)
Becker et al.,
2003
RCT; multicenter;
parallel group
723 4 years 51.5 Yes 5.0 NS on new-onset HT Barbé et al.,
2012
Prospective,
single-center,
long-term follow-up
91 5 years 100 Yes NA NS on 24h BP, SBP and DBP Kasiakogias
et al., 2013
RCT; parallel group 40 6 months 100 Yes 6.01 ↓ Awake SBP (6.5mmHg)
and DBP (4.5mmHg)
NS nocturnal SBP and DBP
Pedrosa et al.,
2013
Retrospective chart
review study
98 1 year 100 Yes 6.3 ↓ 5.6mmHg MBP (resistant
HT group)
↓ 0.8mmHg MBP (controlled
BP group)
Dernaika et al.,
2009
RCT; crossover 28 8 weeks 100 Yes 4.8 ↓ 2.1mmHg 24h MBP (CPAP
group)
↓ 9.1mmHg 24h MBP
(valsartan group)
Pépin et al.,
2009
Prospective cohort
study
86 6 months 55 Yes 4.8 ↓ 4.92mmHg 24h MBP Robinson et al.,
2008
Observational study 24 12 weeks 0 No NA ↓ 5.3mmHg 24h MBP Yorgun et al.,
2014
Prospective cohort
study
196 6 months 85 Yes NA ↓ 2.7mmHg DBP
↓ 2.1mmHg SBP
Börgel et al.,
2004
RCT; multicenter;
double-blinded
340 12 weeks 100 No 4.5 ↓ 1.5mmHg MBP
↓ 1.3mmHg mean DBP
↓ 2.1mmHg mean SBP
Durán-Cantolla
et al., 2010
RCT; multicenter;
parallel group
44 6 weeks NA Yes 5.0 NS on 24h SBP and DBP Barbé et al.,
2001
RCT; crossover
study; sham placebo
35 10 weeks 100 Yes 5.2 NS on overall 24 h MBP Robinson et al.,
2006
Observational,
monocentric; cohort
study
495 3.4 years 40.4 Yes NA ↓ Occurrence of systemic
arterial HT
Bottini et al.,
2012
(Continued)
Frontiers in Physiology | Integrative Physiology September 2014 | Volume 5 | Article 361 | 4
Diogo and Monteiro Antihypertensive drugs in CIH conditions
Table 1 | Continued
Study design n Study
duration
HT patients (%) AHDs (Y/N) Mean CPAP use
(h/night)
BP outcome References
RCT; single-blinded 44 13.2 weeks 100 Yes 5.1 Additional ↓ in office BP and
ambulatory BP monitoring
(CPAP+ 3 AHDs)
Litvin et al., 2013
RCT, multicenter 359 1 year 100 Yes 4.7 ↓ 2.19mmHg DBP NS
↓ 1.89mmHg SBP NS
Barbé et al.,
2009
RCT 36 3 months NA No 5.2 ↓ 2mmHg office DBP
↓ 5mmHg office SBP
↓ 5mmHg 24h DBP
↓ 5mmHg 24h SBP
Drager et al.,
2011
RCT; parallel group 64 3 months 100 Yes >5.8 ↓ 6.98mmHg 24h DBP
↓ 9.71mmHg 24h SBP
Lozano et al.,
2010
AHDs, antihypertensive drugs; BP, blood pressure; CPAP, continuous positive airway pressure; DBP, diastolic blood pressure; HT (%), percentage of hypertensive
patients; MBP, mean blood pressure; NA, information not available; NS, no significant effect; RCT, randomized controlled trials; SBP, systolic blood pressure; ↓,
decrease.
additional care must be taken to minimize external factors (e.g.,
light exposure, photoperiod, noise, disruptions in the home
environment, and post-surgical care in studies, for instance
requiring implantation of telemetric devices) able to influence
sleep in animals used in experimental research (reviewed in
Toth and Bhargava, 2013).
The experimental animal models developed to mimic OSA
have recently been reviewed (Dematteis et al., 2009; Golbidi
et al., 2012; Davis and O’Donnell, 2013; Toth and Bhargava,
2013) and assembled taking into account the main injuries trig-
gered by OSA. Despite attempts to use large animals (e.g., dogs,
lambs, and pigs) to simulate upper airway obstruction, most
research on the cardiovascular consequences of OSA has been
performed in rodents. Alternative models (e.g., cell cultures
incubated in specific devices that perform oxygen fluctuations
mimicking sleep apnea-related IH), mainly relevant to signal-
ing investigation (Kumar et al., 2003; Gozal et al., 2005; Ryan
et al., 2005), represent a complementary approach to the most
widely used sleep models. However, in spite of the recommen-
dations to refine, reduce and replace (the 3Rs programme),
these alternative models cannot replace animal models in the
study of HT.
The natural models of sleep apnea include the English bull-
dog, the historic natural model of spontaneous obstruction
(Hendricks et al., 1987), the sleep-related central apnea models
[e.g., Sprague-Dawley rats (Carley et al., 2000), spontaneously
hypertensive (SH) rats (Carley et al., 1998), C57BL/6J (Julien
et al., 2003; Liu et al., 2010)], and the Zucker obese rat in which
apnea is obesity-related (Ray et al., 2007; Lee et al., 2008; Iwasaki
et al., 2012). The experimentally-induced models (e.g., the sleep
deprivation model, induced airway obstruction and the CIH
model) are the most widely used. Due to model limitations and
lack of extensive study, we only briefly describe the induced airway
obstruction model and the sleep deprivation model. Special focus
will be given to the CIH model, based on the assumption that IH
is the most effective paradigm to induce HT related to OSA and
probably the most relevant stimulus regarding the cardiovascular
sequelae of OSA.
Induced airway obstruction model
Briefly, the airway obstruction model involves surgical interven-
tion (an endotracheal tube), which is an invasive procedure, or
alternatively the use of a specific chamber with a latex neck collar
that induces recurrent airway obstruction. This latter procedure,
developed by Farré et al. (2007), is associated with high levels
of stress due to the restriction of animal movement. In both
approaches, the degree of obstruction is adjustable (Golbidi et al.,
2012) and in the case of induction of obstruction through endo-
tracheal tube, the PaCO2 can be adjusted to mimic human sleep
apnea (Golbidi et al., 2012). Many experiments using this method
have not monitored the sleep state of the animals, but more recent
studies have incorporated sophisticated apparatus that is able to
detect sleep-awake states and allow close coordination between
the initiation of airway obstruction and sleep onset (Schneider
et al., 2000).
This model allows the study of the potential consequences of
strenuous breathing against an obstructed airway and can be used
to study the cardiovascular consequences and risk factors of OSA
(e.g., systemic inflammation and coagulation), and to investigate
the mechanisms that underlie OSA (Salejee et al., 1993; Nácher
et al., 2007, 2009; Almendros et al., 2008, 2011; Othman et al.,
2010). However, to the best of our knowledge, no study has yet
shown that this obstruction model is able to mimic HT related
to OSA. Furthermore, when testing AHDs, it became crucial to
ensure the selection of a stress-free paradigm as it has been shown
that any source of external stress on rodents can significantly
increase heart rate and blood pressure (Brown et al., 2000; Kramer
et al., 2000; Balcombe et al., 2004; Bonnichsen et al., 2005) and
therefore contribute to confounding the experimental results.
Finally, as the rat models of obstruction or asphyxia were devel-
oped in restrained or anesthetized rats, they are not good models
for chronic administration of oral drugs, particularly AHDs.
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Sleep deprivation model
In the last few years, several approaches have been used to trigger
sleep deprivation in different animals, the rat being the animal of
choice to date (Colavito et al., 2013). In the “multiple platform
technique,” the animal is aroused from sleep when the charac-
teristic loss of muscle tone that accompanies paradoxical sleep
causes it to fall off the platform (Suchecki and Tufik, 2000). The
“gentle handling” procedure, by far the most popular method, is
based on direct interaction with the experimenter, who actively
keeps the animal awake through the use of external stimulation
(e.g., mild noises, tapping or gentle shaking of the cage, or by
direct contact with the animal either using a soft brush or by
hand), or by the introduction of novel objects or nesting material
in the cages, which typically leads to active exploratory behavior
(Colavito et al., 2013).
These models are most often used to evaluate the neurophys-
iological aspects of OSA (Van Dongen et al., 2003; Haack and
Mullington, 2005; McKenna et al., 2007; Ward et al., 2009; Nair
et al., 2011) due to the high similarity between the structures of
the nervous systems of rodents and humans (Badran et al., 2014),
and to illustrate some mechanistic pathways induced by this trig-
ger (McGuire et al., 2008; Tartar et al., 2010; Liu et al., 2011;
Perry et al., 2011). Nevertheless, some studies have also aimed to
evaluate the cardiovascular outcomes induced by this OSA fea-
ture and have suggested that sleep fragmentation may have a far
more important role in cardiovascular changes observed in OSA
patients (Golbidi et al., 2012). Even so, sleep deprivation studies
have produced mixed results regarding BP outcomes.
In 1997, Brooks et al. suggested that sleep fragmentation, trig-
gered by auditory stimulus, induced only acute changes in BP
and did not affect daytime BP (Brooks et al., 1997a,b). In the
same way, Bao et al.’s results showed that sleep fragmentation in
rats, using acoustic stimuli for 35 days, did not elicit an increase
in BP, probably due to some adaptation behavior (Bao et al.,
1997). However, more recent studies have shown that sleep depri-
vation leads to increased plasma concentrations of epinephrine
and norepinephrine (Andersen et al., 2005), ET-1/2 levels (Palma
et al., 2002), and increased heart rate and systolic blood pres-
sure (Andersen et al., 2004; Perry et al., 2007). In addition,
sleep fragmentation enhances plasma inflammatory cytokines
(e.g., TNF-α, IL-6, IL-1α, and IL-1β), leading to increased oxida-
tive stress and inflammation (Yehuda et al., 2009). These results
add further evidence demonstrating that sleep deprivation may
lead to serious cardiovascular consequences and may aggravate
hypertensive features. However, despite the potential of the sleep
deprivation model to induce HT related to OSA, it does not
exactly mimic sleep fragmentation and presents one major short-
coming regarding the evaluation of AHDs efficacy that should be
taken into account. Sleep deprivation is a stressful method and
it is still unclear whether the method is itself a stressful stimulus
(Palma et al., 2002). Thus, in conclusion, sleep deprivation mod-
els are useful tools for unveiling various aspects of sleep function,
studying the effects of sleep loss on subsequent brain function
at the molecular, cellular and physiological levels, and evaluating
cognitive impairment, but should be used with caution when-
ever stress can act as a confounding factor and compromise data
interpretation.
CIH model
IH is now established as the dominant model of sleep apnea.
Generally, this model makes use of specific ventilated chambers
in which the animals are housed and cyclically exposed either
to normoxia/hypoxia or room air to mimic the most relevant
consequences of OSA. Hypoxic conditions can also be achieved
by surgical intervention (an endotracheal tube) or by the use of
a mask, which involves animal restraint and consequently high
levels of stress (Golbidi et al., 2012). In either case, animals
breathe nitrogen-enriched air alternating with oxygen or normal
air (Dematteis et al., 2009). Thus, as with O2, nitrogen plays an
important role in this model as the flushing of the chambers
with this gas allows the gradual lowering of O2. The duration
of the hypoxic and normoxic phases of the IH cycle, as well as
the slopes of FiO2, decrease and increase, and are dependent on
cage/chamber size and the gas flows and mixtures (Dematteis
et al., 2009).
The standard animal model of OSA was that described in
the landmark study of Fletcher and Bao (1996). Despite the
presence of some drawbacks, this model has successfully been
employed to study the changes in systemic arterial pressure and
the impact of IH on a wide range of cardiovascular outcomes.
One of the major limitations pointed to in this model is the
absence of recurrent upper airway obstruction, abolishing the
acute hemodynamic changes due to the negative intrathoracic
pressure (Badran et al., 2014). Marked negative intrathoracic
pressure induces acute hemodynamic changes that are probably
the starting point for chronic cardiovascular diseases (Bonsignore
et al., 1994). Despite the absence of upper airway occlusion, some
respiratory efforts (intermittent tachypnea) occur, correspond-
ing to a fluctuating hyperventilation that follows the IH cycles
(Dematteis et al., 2009). However, this disadvantage allows the
evaluation of CIH effects, namely chronic blood gas exchanges,
without the interference of the mechanical aspects of OSA.
This model also fails to reproduce the transient hypercapnia,
or at least eucapnia, which occurs in humans determined by air-
way occlusion. The first question concerning this issue should
be: is PaCO2 relevant in humans? Hypercapnia is not a standard
parameter analyzed in polysomnographic recordings in patients
and therefore there is no consensus on the impact of PaCO2 in
arterial blood pressure in patients with OSA. In clinical stud-
ies of patients with moderate OSA, the changes in PaCO2 have
seemed to be irrelevant (Epstein et al., 2001) or have shown a
slight increase (Tilkian et al., 1976) during the apneic events.
However, a PaCO2 increase may contribute to the severity of the
cardiovascular consequences of OSA (Cooper et al., 2005). The
results shown by Fletcher et al. in rats suggest that the exposure
to hypercapnia during IH is not a critical factor as the effect of
IH on diurnal BP is similar, independently of the lower or higher
levels of CO2 (Fletcher et al., 1995). Moreover, Bao et al. found
that eucapnic IH in rats is a more powerful stimulus for induc-
ing acute BP increase than hypocapnic IH (Bao et al., 1997).
Similarly, Lesske et al. showed comparable changes in BP between
two groups submitted to IH with or without hypercapnia (Lesske
et al., 1997). On the other hand, based on the results of differ-
ent CIH experimental protocols in rodents, Kanagy concludes
that the level of PaCO2 influences the magnitude of an increase
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in BP (Kanagy, 2009). Concretely, eucapnic hypoxia induces a
faster and greater increase than hypocapnic hypoxia (Kanagy,
2009), through mechanisms that presently remain unknown.
Moreover, the greatest increases in BP have been observed in stud-
ies in which hypocapnia was prevented by CO2 administration
(Morgan, 2009). Likewise, Tamisier et al., in a study performed
in humans, reported that hypercapnic hypoxia leads to greater
sympathetic activation than hypocapnic hypoxia (Tamisier et al.,
2009). In line with these findings, the presence of hypocap-
nic or eucapnic hypoxia conditions leads to an underestimated
increase in BP that must be taken into account. In conclusion,
although some data suggest that PaCO2 may influence physiolog-
ical responses to IH, further studies are needed to evaluate the
combined effect of IH and hypercapnia. Another drawback that
could be attributed to the IH paradigm is the fact that it is not
accompanied by sleep fragmentation and does not incorporate
monitoring of sleep.
Each group of researchers has applied its own specific
paradigm and these discrepancies may compromise the straight-
forward comparison of the results. The several paradigms of CIH,
which simulate the cyclical pattern of hypoxia experienced by
patients with OSA, diverge in some respects, namely in the animal
species involved, e.g., Sprague-Dawley rats (Fletcher et al., 1995;
Kanagy et al., 2001; Tahawi et al., 2001; Allahdadi et al., 2005;
Chen et al., 2005; Phillips et al., 2005; Lai et al., 2006), Wistar
rats (Dunleavy et al., 2005; Lefebvre et al., 2006), C57BL/6J mice
(Julien et al., 2003), and CF-1 mice (Rosa et al., 2011), the sever-
ity of hypoxia, the number of hypoxic episodes per hour of sleep,
the number of days of hypoxic exposure (exposure duration), and
CO2 manipulation. Table 2 summarizes the variability observed
in the CIH models.
These models typically create moderate to severe oxygen
desaturation, thereby mimicking severe forms of OSA and may
therefore not be applicable to mild and moderate clinical OSA
(Dematteis et al., 2009). CIH models with cycles of FiO2 of 5% or
less usually mimic severe forms of OSA in humans and produce
maximal changes in BP and heart rate (Dematteis et al., 2008).
However, higher FiO2 (8–10%) has been used in rodent models
of CIH (Soukhova-O’Hare et al., 2008; Knight et al., 2011; Perry
et al., 2011; Bathina et al., 2013).
The duration and frequency of hypoxic/normoxic periods
are adjustable; usually, the higher the frequency the shorter the
IH cycles (Golbidi et al., 2012). There is a sizeable discrepancy
regarding the duration of IH cycles, ranging from 120 cycles/h
(30 s cycle; Fletcher et al., 1992a; Julien et al., 2003; Dematteis
et al., 2008), 80 cycles/h (6min cycle; Knight et al., 2011), 60
cycles/h (1min cycle; Campen et al., 2005), and when the cham-
bers are larger, longer cycles are often used, reducing the number
of cycles/h (Zoccal et al., 2007, 2008; Silva and Schreihofer, 2011)
of daytime exposure, from 4 h/day (Kalaria et al., 2004), 6 h/day
(Lai et al., 2006), 7 h/day (Fletcher et al., 1992a), 8 h/day (Chen
et al., 2005; Belaidi et al., 2009; Zoccal et al., 2008, 2009; Knight
et al., 2011; Silva and Schreihofer, 2011; Dyavanapalli et al., 2014;
Schulz et al., 2014), 10 h/day (Liu et al., 2013) to 12 h/day (Lin
et al., 2007). The exposure duration of 8 h/day seems to be that
on which there is the greatest consensus (see Table 2). The dura-
tion of exposure seems to affect the study outcomes more than
the hypoxic nadir or the rate of hypoxic cycling (Davis and
O’Donnell, 2013).
An advantage of CIH models is they allow exposures that can
be extended over months, enabling the investigation of chronic
consequences that might occur in humans (Toth and Bhargava,
2013). The number of days necessary to induce an increase
in BP seems to be dependent on the CIH paradigm. Some
authors suggest that the BP increase triggered by CIH represents
a time-dependent effect (Prabhakar et al., 2001; Hui et al., 2003;
Dematteis et al., 2008; Zoccal et al., 2009). Moreover, both the
time and severity of hypoxia have been shown to play an impor-
tant role in the cardiovascular response (Li et al., 2007; Perry
et al., 2007). It has recently been shown that a period of 14 days
is not long enough to induce structural changes in cardiovascular
structures, but these are already apparent after 35 days of incuba-
tion (Dematteis et al., 2008). Moreover, Iturriaga et al. report that
the exposure of rats to CIH for 14 days enhanced the ventilatory
response to hypoxia and produced a significant shift in heart rate
variability, but these cardiorespiratory alterations occurred with-
out noticeable changes in mean arterial BP until 21 days of CIH
exposure (Iturriaga et al., 2010). Whereas some short-term pro-
tocols (7–14 days) cause a significant increase in BP (Belaidi et al.,
2009; Knight et al., 2011; Silva and Schreihofer, 2011; Bathina
et al., 2013), others show an increase in BP that occurs only after
long-term exposure (35 days) to CIH (Prabhakar et al., 2001,
2005; Chen et al., 2005; Zoccal et al., 2009) (see Table 2). Finally,
most IH paradigms in rodents do not include CO2 supplementa-
tion (Fletcher et al., 1999; Lin et al., 2007; Iturriaga et al., 2010;
Perry et al., 2011; Bathina et al., 2013). In fact, only some authors
have manipulated the CO2 levels (Ooi et al., 2000; Kantores et al.,
2006; Dyavanapalli et al., 2014) and fixed the values along the
protocol (see Table 2).
Independently of the paradigm used to induce HT related to
OSA, previous reviews are unanimous in reporting the develop-
ment of mild HT, despite the divergent changes in arterial blood
gases (Kanagy, 2009) (see Table 2). The exceptions found in this
review (Kalaria et al., 2004; Belaidi et al., 2009; Iturriaga et al.,
2010; Perry et al., 2011) are all related to the method used for
BP measurement. It is apparent that arterial catheterization is not
an accurate method of measuring BP in CIH models. The meth-
ods most often used for BP measurement (for a review, see Kurtz
et al., 2005) in IH models (see Table 2) are the tail-cuff method
(Allahdadi et al., 2005; Chen et al., 2005; Soukhova-O’Hare et al.,
2008; Belaidi et al., 2009; Totoson et al., 2013), radiotelemetry
(Fletcher, 2000; Tahawi et al., 2001; Lai et al., 2006; Knight et al.,
2011; Bathina et al., 2013; Sharpe et al., 2013; Dyavanapalli et al.,
2014; Schulz et al., 2014), and arterial catheterization (Kanagy
et al., 2001; Kalaria et al., 2004; Campen et al., 2005; Lin et al.,
2007; Belaidi et al., 2009; Zoccal et al., 2009; Iturriaga et al., 2010;
Perry et al., 2011; Silva and Schreihofer, 2011; Totoson et al.,
2013).
HUMANS
The variety of models of IH in healthy human subjects is much
less impressive than that observed for animal models of sleep
apnea. In terms of the exposure time, these models are usu-
ally divided into short-term and chronic (Foster et al., 2007). In
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Table 2 | Reports on the effects of CIH on blood pressure.
Species Hypoxia cycle, Nadir FiO2, duration
and CO2 manipulation (Y/N)
BP measurement Effect on BP References
Sprague-Dawley rats 20 cycles (90 s each) of 21–5% O2 and
0–5% CO2/h; 7 h/day; 35 days; Yes
Tail-cuff method ↑ MAP (25–28mmHg) Allahdadi et al.,
2005
Sprague-Dawley rats 80 cycles (6min each) 21–10%
O2/day; 8 h/day; 7 days; No
Telemetry ↑ MAP (7–10mmHg) Knight et al., 2011
Sprague-Dawley rats 5% O2 12 times/h; 8 h/day; 7–21 days;
No
Arterial catheterization No changes in MAP Iturriaga et al., 2010
Wistar rats 10% O2 for 4 h/day and 21% O2 for
20 h/day; 56 days; Yes (PCO2 <
0.02%)
Arterial catheterization No differences in
systemic pressure
Kalaria et al., 2004
Sprague-Dawley rats 2/3–20.9% O2 (3–6 s +15–18 s; 2
cycles/min); 6–8 h/day; 35 days; No
Telemetry ↑ MAP (16mmHg) Tahawi et al., 2001
C57BL/6J mice 21–5% O2 (60 s); 12 h/day; 5 weeks;
No
Arterial catheterization ↑ Systemic BP
(7.5mmHg)
Campen et al., 2005
SHR + Wistar rats 21–10% O2 (1min cycles: 20 s +
40 s); 8 h/day; 14 days; No
Tail-cuff method + Arterial
catheterization
Enhanced HT
development in SHR +
NS in Wistar rats
Belaidi et al., 2009
Sprague-Dawley rats 2/3–20.9% O2 (3–6 s + 12 s; 2
cycles/min); 6–8 h/day; 35 days; No
Telemetry ↑ MAP (10mmHg) Fletcher, 2000
LCR and HCR 21–10% O2 (3min cycles); 8 h/day; 7
days; No
Telemetry ↑ MAP in both groups Sharpe et al., 2013
Sprague-Dawley rats 20 cycles (90 s each) of 21–5% O2 and
0–5% CO2/h; 8 h/day; 11 days; Yes
Arterial catheterization ↑ MAP (30mmHg) Kanagy et al., 2001
Sprague-Dawley rats 48 cycles (45 + 30 s) 20.9–2/6% O2/h;
6 h/day; 30 days; No
Telemetry ↑ MAP (19.3mmHg) Lai et al., 2006
C57BL/6J mice 21–5.7% O2 (alternating every 6min);
12 h/day; 90 days; No
Arterial catheterization ↑ MAP (19.8mmHg) Lin et al., 2007
Sprague-Dawley rats 21–10% O2 for 5 s every 90 s;
10 h/day; 4 weeks; No
Tail BP telemeter ↑ MAP (37mmHg) Liu et al., 2013
SHR 21–10% O2 (alternating every 90 s);
12 h/day; 30 days; No
Tail-cuff method ↑ SBP and DBP (NA
mmHg)
Soukhova-O’Hare
et al., 2008
Sprague-Dawley rats 21–4/6% O2 (every 60 s); 8 h/day; 5
days/week; 5 weeks; No
Tail-cuff method ↑ MAP (12mmHg) Chen et al., 2005
Wistar rats 1min cycles with 30 s of a 5% FiO2;
8 h/day; 14–21 days; No
Tail-cuff method + Arterial
catheterization
Rapidly ↑ MAP (NA
mmHg)
Totoson et al., 2013
Sprague-Dawley rats 21–6% O2 (9min cycles); 8 h/day; 14
days; No
Arterial catheterization ↑ MAP (9mmHg) Silva and
Schreihofer, 2011
Wistar rats 20.8–6% O2 (9min cycles: 5min Nx);
8 h/day; 10 days; No
Arterial catheterization ↑ MAP (12mmHg)
↑ SBP (9mmHg)
↑ DBP (8mmHg)
Zoccal et al., 2009
Wistar- Hannover rats 21–10% O2 (2min + 2min);
1000–1600 h; Yes (PCO2 < 0.01%)
Arterial catheterization No differences in MAP Perry et al., 2011
(Continued)
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Table 2 | Continued
Species Hypoxia cycle, Nadir FiO2, duration
and CO2 manipulation (Y/N)
BP measurement Effect on BP References
Sprague-Dawley rats 10 cycles (6min each) of 21–6% O2
and 0–5% CO2/h; 8 h/day; 28 days;
Yes
Telemetry ↑ SBP (39mmHg)
↑ DBP (33mmHg)
Dyavanapalli et al.,
2014
C57BL/6J mice 21–7% O2 (120 s each cycle); 5
days/week; 8 h/day; 6 weeks; No
Telemetry Significant ↑ MAP Schulz et al., 2014
Sprague-Dawley rats 21–10% O2 (cycle duration: NA);
8 h/day; 7 days; No
Telemetry ↑ MAP that persisted
after CIH exposure
Bathina et al., 2013
BP, blood pressure; CIH, chronic intermittent hypoxia; DBP, diastolic blood pressure; h, hour; HCR, high aerobic capacity rats; HT, hypertension; LCR, low aerobic
capacity rats; MAP, mean arterial pressure; NA, information not available; NS, no significant effect; Nx, normoxia; min, minutes; s, seconds; SBP, systolic blood
pressure; SHR, spontaneously hypertensive rats; ↑, increase.
short-term IH models, generally the exposure time (20–60min)
and the duration of the hypoxia or voluntary apnea period (30 s)
are very limited. The protocols of Cutler et al. and Tamisier et al.
are good examples of short-term models (Cutler et al., 2004;
Tamisier et al., 2009). In contrast, Foster et al. made use of a
chronic model, exposing healthy human volunteers to an hour
of IH (5min hypoxia alternating with 5min normoxia) daily for
2 weeks (Foster et al., 2005). As in the animal models of IH,
only some studies have controlled the level of CO2 (Foster et al.,
2005), whereas others have not (Tamisier et al., 2009). Regardless
of the protocol followed, exposing humans to CIH implies careful
supervision.
In 2001, Xie et al. exposed nine healthy human subjects dur-
ing wakefulness to 20min of isocapnic hypoxia (arterial O2
saturation, 77–87%) and 20min of normoxic hypercapnia (end-
tidal PCO2, 15.3–8.6 Torr above eupnea) on two separate days.
The subjects breathed through a leak-free nasal mask and the
neurocirculatory and ventilatory responses to these two stimuli
were further evaluated (Xie et al., 2001). These authors found
that hypoxia induced a sympathetic activation that outlasted
the chemical stimulus, whereas hypercapnia evoked a short-lived
sympathetic activation (Xie et al., 2001). Years later, in a study
performed with a larger sample (n = 31), Cutler et al. used a
model of IH induced by voluntary apnea (30 s of hypoxic apnea
every 1min—simulating an AHI of 60/h—for 20min) to deter-
mine if the cessation of breathing is important in prolonged sym-
pathetic activation (Cutler et al., 2004). This study also included
two other groups that were exposed to intermittent hypercap-
nic hypoxia and to intermittent isocapnic/hypoxia, respectively
(Cutler et al., 2004). Their results support the hypothesis that
short-term exposure to intermittent hypoxic apnea results in sus-
tained elevation of post-ganglionic muscle sympathetic nerve
activity and that hypoxia is the primary mediator of this response
(Cutler et al., 2004). The data reported by Leuenberger et al.
one year later were in line with these results (Leuenberger et al.,
2005). They also found, in a study that enrolled 26 patients, a
sustained sympathetic activation and also a transient elevation of
BP following 30min of voluntary end-expiratory apneas primed
with a hypoxic gas mixture and lasting for 20 s in each minute
(Leuenberger et al., 2005).
Foster et al. carried out three main studies in healthy human
volunteers. The first aimed to determine the ventilatory, cardio-
vascular and cerebral tissue oxygen response to two protocols of
IH (Foster et al., 2005). This study involved 18 patients randomly
assigned to short-duration IH (1 h of 12% O2 separated by 5min
of normoxia) or long-duration IH (30min of 12% O2). Both
groups had 10 exposures over 12 days. Their findings show a rise
in mean arterial blood pressure (MAP) that occurs throughout
the daily exposure to short-duration IH but not during expo-
sure to long-duration IH; moreover, they demonstrate that the
vascular processes required to control blood flow and O2 sup-
ply to cerebral tissue in a healthy human are delayed following
exposure to 12 days of isocapnic IH (Foster et al., 2005). In 2009,
the same group reinforced the enrollment of IH on the patho-
genesis of cardiovascular and cerebrovascular disease in patients
with OSA (Foster et al., 2009). They exposed 10 healthy subjects
to IH (2min of hypoxia: nadir PET,O2 = 45.0mmHg, alternat-
ing with 2min of normoxia: peak PET,O2 = 88.0mmHg for 6 h)
for 4 consecutive days and concluded that IH alters BP (MAP
increased by 4mmHg) and induces an increase in cerebral vascu-
lar resistance (Foster et al., 2009). More recently, Foster et al. have
assessed the role of the type I angiotensin II receptor in mediat-
ing an increase in arterial pressure associated with a single 6-h IH
exposure (Foster et al., 2010). For that, they exposed nine healthy
subjects to sham IH, IHwith placebomedication, and IHwith the
type I angiotensin II receptor antagonist (losartan). Their find-
ings demonstrate a significant increase in arterial pressure after
exposure to isocapnic IH (Foster et al., 2010). Furthermore, since
this increase is prevented by the blockade of AT1 receptors, these
results suggest an important role for the rennin-angiotensin-
aldosterone system (RAAS) in the pathophysiology of HT related
to OSA (Foster et al., 2010).
Tamisier et al. have developed a novel model of nocturnal
CIH in healthy humans, which represents an important step
forward in the field, designed to overcome some of drawbacks
and confounding factors that are present in studies of both
animals and OSA patients (Tamisier et al., 2009). To investi-
gate the effects of CIH on sleep, BP and ventilatory control,
these authors make use of altitude tents to mimic the cyclical
arterial oxygen desaturations-resaturations of sleep apnea. They
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delivered O2 for 15 s every 2min during sleep while subjects
breathed 13% O2 in a hypoxic tent to create 30 cycles/h of cyclic
desaturation-reoxygenation (SpO2 range: 95–85%), and exposed
subjects overnight for 8–9 h/day for 2 or 4 weeks (Tamisier et al.,
2009). Among other results, they show that waking normoxic
arterial pressure increased significantly at 2 weeks for systolic and
for diastolic at 4 weeks, that patients developed a sustained BP
increase during the day and exhibited a steeper BP decrease at
night compared to baseline BP values, and finally, that this model
produces clinically relevant fluctuations in SaO2 (Tamisier et al.,
2009). Although undoubtedly relevant, the authors recognize the
presence of several respects in which their model does not mimic
sleep apnea, e.g., no negative intrathoracic pressure development,
higher percentage of sleep time at <90% SaO2 and poikilocapnia
(Tamisier et al., 2009). However, some of these limitations can
be overcome to achieve a pattern of IH more akin to OSA fea-
tures. This model was further used by the same group in 2011 to
shed light on the profile of the BP increase previously described
to determine if it is sustained and to explore potential under-
lying physiological mechanisms. The authors found that only 2
weeks of severe IH exposure produces a sustained daytime BP
increase in the setting of sympathetic activation and blunted vas-
cular sympathic baroreflex gain in healthy volunteers (Tamisier
et al., 2011).
In conclusion, to date, only a small number of studies have
been conducted using healthy human models of IH and these
have primarily been aimed at elucidating the role of IH in sus-
tained sympathetic activation and cerebrovascular regulation.
Only a few studies have evaluated BP outcomes (Foster et al.,
2009, 2010; Tamisier et al., 2009, 2011) and none of these models
have truly been used to assess the efficacy of AHDs in the treat-
ment of HT related to OSA. In fact, in the later work of Foster
et al., losartan (the angiotensin II AT1 receptor antagonist) was
used only to demonstrate a mechanistic pathway rather than to
evaluate its efficacy (Foster et al., 2010). Thus, future research in
this field is clearly needed.
WHAT ARE THE MECHANISMS INVOLVED IN THE
PATHOGENESIS OF HT RELATED TO OSA?
Fletcher et al. were pioneers in demonstrating the hyperten-
sive effect of CIH (Fletcher et al., 1992a) and the role of the
sympathetic nervous system, peripheral receptors and rennin-
angiotensin system in this response (Fletcher et al., 1992b, 1999,
2002; Fletcher, 2000). This group also showed that surgical dener-
vation of peripheral chemoreceptors, adrenal demedullation and
chemical denervation of the peripheral nervous system prevented
the increase in BP in response to CIH stimulus (Fletcher et al.,
1992b; Bao et al., 1997). After Fletcher et al.’s first work, many
reports enabled confirmation of the relationship between IH and
BP increases and contributed to elucidating the underlying mech-
anisms. Kanagy et al. reported increased plasma endothelin-1
levels in rats exposed for 11 days to CIH, which also demon-
strated an appreciable increase in MAP (Kanagy et al., 2001).
In 2006, Lai et al. suggested that chronic IH-induced sustained
HT was associated with the facilitation of cardiovascular sympa-
thetic outflow followed by decreases in baroreflex sensitivity in
conscious rats (Lai et al., 2006). Along the same line, the work
undertaken by Zoccal et al. provided strong evidence to sup-
port the idea that rats submitted to CIH show an increase in
sympathetic activity, which seems to be essential in the mainte-
nance of high BP values in the CIH model (Zoccal et al., 2007).
Another group revealed that although elevated sympathetic ner-
vous system activity (SNA) may contribute to CIH-induced HT,
reduced adrenergic vascular reactivity buffers the cardiovascular
impact of exaggerated acute raises in SNA (Silva and Schreihofer,
2011). Data attained by Knight et al. indicated that CIH induces
an increase in FosB/FosB in autonomic nuclei and suggested
that activator protein-1 (AP-1) transcriptional regulation may
contribute to stable adaptative changes that support chroni-
cally elevated BP (Knight et al., 2011). Also in 2011, Liu et al.
demonstrated that CIH activates the HIF-1α/endothelin system,
through CIH-NADPH oxidase-mediated ROS production, and
this enhances the development of resistant vasoconstriction and
elevates BP in rats (Liu et al., 2011). The study undertaken by
Bathina et al. revealed that the knockdown of tyrosine hydrox-
ylase in the nucleus of the solitary (NTS) tract reduces the
CIH-induced persistent increase in MAP, suggesting that nora-
drenergic A2 neurons in nucleus tractus solitarius play a role
in the cardiovascular responses to CIH (Bathina et al., 2013).
More recently, Schulz et al. have shown that NADPH oxidase
2 (NOX2) knockout blocks the development of HT induced by
CIH, suggesting that this type of HT is mediated by reactive oxy-
gen species (ROS) derived from the activation of NOX2 within
cells located outside the cardiovascular system (Schulz et al.,
2014).
The mechanisms involved in the genesis of HT related to OSA
have recently been reviewed (Lavie and Lavie, 2009; Bosc et al.,
2010; Sunderram and Androulakis, 2012; Zhang and Si, 2012;
Lévy et al., 2013) and broadly include the following: sympa-
thetic nervous system stimulation mediated mainly by the activa-
tion of carotid body chemoreflexes, decreased vascular responses
to nitric oxide, increased plasma concentrations of endothe-
lin, and elevation of proinflammatory cytokines (TNF-α, IL-6,
VEGF). While for some of these mechanisms (e.g., activation
of the RAAS, endothelial dysfunction, systemic inflammation,
metabolic anomalies, and genetic contribution) the relationship
with OSA and subsequent cardiovascular morbidity remain par-
tially unclear and there is a need to gather more evidence, for
others (e.g., the increase in sympathetic activity and acute effects
of negative intrathoracic pressure), there seems to be more agree-
ment on the linkage and it is well-documented (Parati et al.,
2013). In fact, based on data attained from patients with OSA,
it is widely accepted that sympathetic activation, inflammation
and oxidative stress play major roles in the pathophysiology of
this particular type of HT. In addition, the use of animal models
has revealed that CIH is the critical stimulus underlying sympa-
thetic activity and HT, and that this effect requires the presence
of functional arterial chemoreceptors (Fletcher, 2000). However,
it should be also mentioned that HT related to OSA probably
results not only from increased carotid chemoreflex but also from
decreased baroreceptor activity (Dumitrascu et al., 2013). It is also
important to highlight the potential role of obesity as an interme-
diate factor in the pathway of HT related to OSA (Young et al.,
2007; O’Connor et al., 2009).
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The mechanisms involved in the pathogenesis of HT can be
summarized in relation to two main pathways: sympathetic ner-
vous system stimulation mediated mainly by activation of carotid
body (CB) chemoreflexes and the systemic effects of CIH, mainly
due to the activation of NOX2 and subsequent ROS produc-
tion. Figure 1 illustrates the hypothesized pathways by which
intermittent hypoxia leads to HT.
WHAT IS ALREADY KNOWN CONCERNING THE EFFICACY OF
AHDs?
HUMANS
Despite the considerable number of studies involving OSA
patients, only a few have investigated the efficacy of different
AHDs and in general, they tend to be individual drug studies.
Moreover, most of the studies only take into account the number
of drugs taken by patients to adjust this variable and are difficult
to interpret as most of the patients were already under AHDs reg-
imens. This lack of information could be attributed to the large
number of possible different AHDs regimens observed in OSA
patients. Table 3 summarizes the most relevant studies that have
investigated the efficacy of AHDs in OSA patients.
In a study undertaken by Pelttari et al., the AH effects of four
different AHDs (atenolol: a beta-blocker; isradipine: a calcium
channel blocker; hydrochlorothiazide: a diuretic; spirapril: an
angiotension-converting enzyme inhibitor) in obese patients with
OSA and HT were compared using ambulatory blood pressure
monitoring (ABPM) (Pelttari et al., 1998). This study revealed
that although daytime HT was quite easily controlled by the
single use of these drugs (especially with atenolol and isradip-
ine; diuretics did not significantly lower BP) none of the AHDs
were able to produce a significant decrease in nocturnal BP
(Pelttari et al., 1998). Mayer et al. carried out another compara-
tive study between cilazapril (an angiotension-converting enzyme
inhibitor) and metoprolol (a beta-blocker) (Mayer et al., 1990).
Their findings showed that despite the short period of therapy (1
week), both metoprolol and cilazapril lowered nighttime BP in
OSA patients (Mayer et al., 1990).
A multiple crossover study examined the BP-lowering
effect of the five major AHDs classes (atenolol: beta-blocker;
amlodipine: calcium channel blocker; enalapril: angiotension-
converting enzyme inhibitor; hydrochlorothiazide: diuretic;
losartan: angiotensin receptor blocker) and showed that atenolol
induced the most pronounced effect in lowering BP (Kraiczi
et al., 2000). Atenolol was more efficient in reducing mean night-
time diastolic and systolic BP (measured by ABPM) compared to
amlodipine, enalapril, hydrochlorothiazide, and losartan (Kraiczi
et al., 2000). Salo et al. investigated the effects of four AHDs
(atenolol; isradipine: a calcium channel blocker; hydrochloroth-
iazide; spirapril: an angiotension-converting enzyme inhibitor)
on cardiovascular autonomic control and reactivity in HT OSA
patients (Salo et al., 1999). This group reported that of the four
drugs, only atenolol effected BP variability (Salo et al., 1999).
Thus, the results of these two pilot studies are in line with those
arguing the involvement of the sympathetic system in the patho-
physiology of HT related to OSA, suggesting that beta-blockers, in
particular atenolol, may have beneficial effects beyond BP reduc-
tion in patients with OSA. However, both studies presented low
FIGURE 1 | Schematic diagram summarizing the pathways by which
intermittent hypoxia leads to hypertension. Repetitive obstructive
apneas or hypopneas lead to increased intrathoracic pressure, sleep
fragmentation, recurrent hypercapnia, and intermittent hypoxia (IH). This
last phenomenon plays a pivotal role in triggering several intermediary
mechanisms and molecular pathways that contribute to the initiation and
progression of cardiac and vascular pathology. First, IH enhances
sympathetic nervous system activity, leading to vasoconstriction and
systemic hypertension through RAAS activation, and an increase in
catecholamine secretion and plasma level of vasoconstrictive ET-1. Episodic
hypoxia also favors the stabilization of HIF-1α and the production of ROS,
which is followed by increased expression of NF-κB and decreased NO
bioavailability, the most important vasodilatory molecule synthesized by the
endothelium. AT II and ET-1 both seem to be implicated in vascular
remodeling and ROS formation, which is increased through the activation of
vascular NADPH oxidase and xanthine oxidase. ROS molecules induce a
cascade of inflammatory pathways linked to an overexpression of adhesion
molecules and pro-inflammatory cytokines, and oxidative stress may trigger
sympathetic hyperactivation and vice versa. ROS production is required for
HIF-1α induction and HIF-1α induction is required for ROS production. In
addition, HIF-1α promotes the expression of ET-1 and transcriptional
activation of VEGF and other growth factors. Activation of NF-κB also
seems to be central in inflammation induced by IH due to its regulatory role
in the production of pro-inflammatory mediators (e.g., TNF-α, IL-6, IL-8,
ICAM-1, and CRP). These signaling pathway proteins, combined with
RAAS, decreased expression of eNOS, and increased ROS production and
stabilization of HIF-1, participate in the molecular mechanisms underlying
the endothelial dysfunction induced by IH. Together, these mechanisms
progress to fluid retention, changes in cardiac output and vascular tone, and
vascular remodeling, leading to systemic HT, one of the major
consequences of OSA. AT II, angiotensin II; CA, catecholamine levels; CRP,
C- reactive protein; CB, carotid body; ET-1, endothelin 1; HIF-1α,
hypoxia-inducible factor α; IH, intermittent hypoxia; IL, interleukin; ICAM-1,
(Continued)
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FIGURE 1 | Continued
intercellular adhesion molecule; NO, nitric oxide; eNOS, endothelial nitric
oxide synthase; NF-κB, nuclear factor-κ-light chain enhancer of activated B
cells; RAAS, renin-angiotensin-aldosterone system; ROS, reactive oxygen
species; TNF- α, tumor necrosis factor α; VEGF, vascular endothelial growth
factor.
levels of causation, which could have limited the ability to detect
differences between classes.
Nevertheless, it has been advanced that angiotension-
converting enzyme inhibitors (ACEi) treatment could exacerbate
OSA by inducing upper airway inflammation (Cicolin et al.,
2006). The comparison between chronic treatments of ACEi and
angiotensin AT1 receptor antagonists in terms of AH efficacy and
levels of inflammatory markers has never been performed either
in humans with OSA or in animal models. More recently, other
study compared the effect of doxazosin (an α1- adrenergic recep-
tor antagonist) and enalapril (an angiotensin-converting enzyme
inhibitor) on nocturnal BP control and concluded that the for-
mer has a proportionally poorer effect than the latter (Zou et al.,
2010). In 1994, Grote et al. performed a study aimed at assessing
the effectiveness of cilazapril (an angiotension-converting enzyme
inhibitor) in managing high BP in patients with OSA. Although
the study comprised a small sample size, the results suggested that
cilazapril is effective in reducing BP in all sleep stages (Grote et al.,
1994). In another small study, Heitmann et al. evaluated the effect
of nebivolol (a third generation beta-blocker) on BP reduction
and sleep apnea activity in HT patients with mild to moder-
ate OSA in comparison with valsartan (an angiotensin receptor
blocker) and concluded that the effect of these AHDs were similar
(Heitmann et al., 2010). Despite the same limitations, these stud-
ies highlight the role of the renin-angiotensin-aldosterone system
(RAAS) in the pathophysiology of HT related to OSA.
In two past studies (Lozano et al., 2010; Litvin et al., 2013),
patients either received CPAP in combination with AHDs or
alternatively, the pharmacological treatment alone, allowing the
evaluation of the effects of CPAP and AHDs independently or in
conjunction. In the study undertaken by Lozano et al., patients
were under an AHDs regimenwith at least three drugs at adequate
doses, including a diuretic (Lozano et al., 2010). The authors
noted a significant decrease in the mean 24-h diastolic BP in
patients who received CPAP in addition to conventional treat-
ment, suggesting that resistant HT treated with both CPAP and
AHDs provides greater BP reduction than AHDs alone (Lozano
et al., 2010). However, in patients who used CPAP less than the
average (5.6 ± 1.52 h/night) and for those treated with conven-
tional treatment alone, there was no significant difference in the
24-h ambulatory BP values (Lozano et al., 2010). These find-
ings are in line with those reported by Litvin et al., attained with
patients who received stepped dose titration of AHDs treatment
(valsartan 160mg + amlodipine 5–10mg + hydrochlorothiazide
25mg) for 3 months before CPAP was added (Litvin et al., 2013).
These findings seem to suggest that the best strategy to treat
HT related to OSA involves the combination of OSA treatment
with CPAP and the use of AHDs. This combination is likely to
be more effective in lowering both daytime and nighttime BP
than either treatment alone (Phillips and O’Driscoll, 2013). In
addition, Pépin et al. explored RAAS inhibition using losartan in
a crossover randomized control trial. In this study, the authors
compared the efficacy of CPAP and valsartan in reducing BP in
HT patients with OSA never treated for either condition (Pépin
et al., 2009). They reported that although the BP decrease was
significant with CPAP treatment, valsartan induced a four-fold
higher decrease in mean 24-h BP than CPAP in this specific
sample (Pépin et al., 2009).
In an earlier report, 74 of the 393 OSA patients using AHmed-
ications on a regular basis for more than 6 months were deemed
to have been treated “ineffectively” (Lavie and Hoffstein, 2001),
but the characterization of these medications was not reported.
The same limitation is found in the study of Deleanu et al., which
aimed to study the effect of medication-controlled HT on OSA
patients (Deleanu et al., 2014). The authors suggested that con-
trolled BP abates sleepiness and reduces remaining symptoms
(e.g., headaches, impotence and morning fatigue). These findings
could be much more interesting if the regimens responsible for
these effects were revealed.
In a very recent study, Kario et al. aimed to evaluate the
effects of bedtime dosing of vasodilating (nifedipine, a calcium
channel blocker) vs. sympatholytic (carvedilol, a non-selective β-
blocker/α1-blocker) AH agents on the sleep BP profile in HTOSA
patients (Kario et al., 2014). For this, they made use of a new
BP monitoring method, the trigger sleep BP monitoring (TSP)
method, which is based on the automated fixed-interval measure-
ment function with an additional oxygen-triggered function that
initiates BP measurement when oxygen desaturation falls below
a set variable threshold continuously monitored by pulseoxime-
try (Kario et al., 2014). The BP lowering effects of nifedipine
on the mean and minimum sleep systolic BP were stronger than
those of carvedilol; moreover, sleep systolic BP surge (the differ-
ence between the hypoxia peak systolic BP—SBP—measured by
the oxygen-triggered function and SBP within 30min before and
after the peak SBP) was only significantly reduced by carvedilol
(Kario et al., 2014). Thus, both drugs are effective in decreasing
sleep BP (Kario et al., 2014) but the effect of carvedilol seems to
be relatedmore specifically to the hypoxia stimuli than nifedipine.
Finally, Cichelero et al. recently published the protocol of their
randomized double-blind clinical trial, which seeks to compare
the efficacy of chlorthalidone (a diuretic) with amiloride (also
a diuretic) vs. amlodipine (a calcium channel blocker) as a first
drug option in patients older than 40 years of age with stage I HT
and moderate OSA (Cichelero et al., 2014). The findings of this
study have not yet been reported.
In summary, individual drug studies find that the blockade
of β1-adrenergic receptors (e.g., atenolol and nebivolol) and the
renin-angiotensin-aldosterone (RAA) pathway, including both
ACEi and angiotensin AT1 receptor antagonists, might be help-
ful. Spironolactone (a mineralocorticoid receptor antagonist) has
been proposed has a very useful tool in cases of resistant HT
(Ziegler et al., 2011a,b), a very prevalent condition in OSA
patients (Oliveras and Schmieder, 2013; Solini and Ruilope, 2013)
in which aldosterone levels are generally elevated, as well as for
severe OSA patients (Ziegler et al., 2011a). Moreover, a study
performed by Gaddam et al. (2010) has provided preliminary
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evidence that treatment with this drug substantially reduces the
severity of OSA and improves BP in patients with both OSA and
resistant HT (Gaddam et al., 2010). These results seem promising
but need to be confirmed in further larger studies. In contrast,
despite volume overload appears to play a large role in the devel-
opment of OSA (Owen and Reisin, 2013), diuretics, namely
thiazide, have not been very effective AH agents in OSA patients
without fluid retention (Ziegler et al., 2011b). Calcium channel
blockers, although effective in lowering BP, seem to present an
effect less related to hypoxia stimuli. Moreover, Nerbass et al.
reported that the use of these drugs might impact negatively on
sleep duration in HT patients with OSA (Nerbass et al., 2011).
They reported that the use of calcium channel blockers was asso-
ciated with significant reduction in total sleep time and lower
sleep efficiency (Nerbass et al., 2011). Thus, their prescription can
be questionable in these patients.
Despite the findings of these studies, they present some lim-
itations and important data are missing. The major limitations
comprise the following: the variability of subjects included in
the studies as most of them were performed in non-AHDs naïve
patients; the severity and chronicity of HT, which were not
taken into account and consenquently the clinical relevance of
BP reduction is questionable; the drug effectiveness in reduc-
ing nocturnal BP, which was not assessed in some studies; the
confounding risk factors for HT that might be present in OSA
patients (e.g., obesity) and were not properly addressed in most
studies. Furthermore, we can point out several questions that
are still unanswered, e.g., how many OSA patients are controlled
under monotherapy with beta- blockers, angiotensin-converting
enzyme inhibitors (ACEis), and angiotensin II receptor blockers
(ARBs)? Beta-blockers or RAAS blockers are apparently effective,
but should they be used alone or in combination? How many
OSA patients remain uncontrolled despite the use of two or more
AHDs? How do different AHDs behave when included in an
AHDs regimen? In addition, the impact of these studies in clinical
practice is unknown because epidemiological studies designed to
investigate the AHmedication profile in OSA patients are lacking.
In addition, the more recent recommendations for the manage-
ment of patients with OSA and HT are inconclusive regarding
the use of AHDs and recognize the lack of strong evidence for
the establishment of a first-line AHDs regimen for these patients
(Parati et al., 2013). Other authors support the idea that as there is
no clear evidence for prefering a specific class of AHDs, the selec-
tion should primarily be guided by the patient’s cardiometabolic
profile and associated comorbidities (e.g., obesity, metabolic syn-
drome, diabetes mellitus, and cardiovascular diseases) (Tsioufis
et al., 2010). Moreover, these authors recommend that due to
the lack of relevant trials focused on the use of associations of
AHDs in OSA patients, the choice should rely on current HT
guidelines and the adverse effects of AHDs also need to be con-
sidered (Tsioufis et al., 2010). The limited evidence base restricts
the ability to make informed treatment choices. Thus, larger scale
observational and clinical studies are needed to address these
and possibly other limitations and bring new insights to the
field.
Another problem concerning the studies carried out in
humans is that HT is frequently not recognized in patients with
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OSA (Baguet et al., 2009), and it is important to highlight that
patients with elevated BP who do not carry the diagnosis of
HT may be misclassified as non-HT (Wang and Vasan, 2005).
Consequently, aggressive control of BPmust be warranted in OSA
patients and an accurate method for BP measurement should be
used in the early diagnosis of clinically suspected OSA patients.
Taking into account the advantages and limitations of the several
methods of BP measurement, 24-h ABPM seems to be superior
to office BP measurement and home BP monitoring in diagnos-
ing HT in patients with suspected OSA (for a review, see Parati
et al., 2012).
ANIMALS
As previously stated, a rather wide variety of animal models has
been used to evaluate the cardiovascular consequences of OSA
and to study the cause-effect mechanisms in OSA. As CIH causes
amoderate increase in BP, drugs can be tested further tomodulate
this effect. However, studies aimed at investigating the AH effect
of drugs on animal models are scarce. Table 4 summarizes the
studies that have evaluated the effects of AHDs on BP in animal
models of CIH.
In a study undertaken to clarify the role of renal sympathetic
nerve activity and plasma renin activity (PRA) in the diurnal BP
response to chronic IH, Fletcher et al. demonstrated that the phar-
macological blockade of the RAAS with losartan prevented the
rise in BP induced by CIH (Fletcher et al., 1999, 2002). Losartan
and other angiotensin antagonists (A-779, an Ang-(1–7) antag-
onist; ZD7155, an AT1 antagonist; PD123319, an AT2 receptor
antagonist) were further used by da Silva et al. (2011) to inves-
tigate the role of endogenous angiotensin peptides within the
hypothalamic paraventricular nucleus (PVN) neurons to control
BP in a rat model of CIH-induced HT. These authors concluded
that endogenous angiotensin peptides acting in the PVN con-
tribute to IH-induced increases in MAP observed in this rat
model. In 2013, losartan was used once again to test the role of
the brain RAAS in CIH HT (Knight et al., 2013). The work of this
group provided evidence that brain RAAS contributes to CIH HT
and that brain RAAS appears to be critical for the development
and maintenance of the sustained HT during normoxia (Knight
et al., 2013).
Other groups have found that the systemic administration
of endothelin (ET) receptor antagonists in rodents prevents
the increase in BP during CIH exposure (Kanagy et al., 2001;
Allahdadi et al., 2008; Belaidi et al., 2009). The data provided
by Allahdadi et al. showed that an endothelin receptor antago-
nist (ETA: BQ-123) acutely decreased the MAP dose dependently
in rats exposed to IH but not sham rats, suggesting that target-
ing ETA receptors may be a selective and effective treatment of
HT related to OSA (Allahdadi et al., 2008). Belaidi et al. used
SH rats and bosentan, a mixed endothelin receptor antagonist
(Belaidi et al., 2009). Their results showed that the administra-
tion of bosentan during chronic IH prevented the increase in BP
and reinforced the idea that endothelin antagonists could be use-
ful therapeutic tools in HT related to OSA (Belaidi et al., 2009).
The same effects were reported by Kanagy et al. for PD145065,
a non-selective endothelin receptor antagonist (Kanagy et al.,
2001).
Soukhova-O’Hare et al., designed a study based on the
assumption that ROS and altered L-Ca2+ channel activity may
underlie the post-natal programing of exaggerated BP and cardiac
remodeling (Soukhova-O’Hare et al., 2008). To test this hypothe-
sis, these authors used nifedipine, an L-calcium channel blocker,
and a superoxide dismutase mimetic (MnTMPyP pentachloride);
both attenuated BP (Soukhova-O’Hare et al., 2008). Their results
suggested that Ca2+ and reactive oxygen species-mediated sig-
naling during IH are critical mechanisms underlying post-natal
programing of an increased severity of HT in SH rats. Kumar
et al. reported similar results for the same superoxide dismutase
mimetic (Kumar et al., 2006). A year before, Troncoso Brindeiro
et al. used another superoxide dismutase mimetic, tempol, and
showed that scavenging superoxide prevents both the increase
in ET-1 production and vascular ROS levels induced by CIH
exposure (Troncoso Brindeiro et al., 2007). The later work of
Del Rio et al., using the antioxidant ascorbic acid, showed that
this substance prevented the increased plasma peroxidation and
nitrotyrosine formation within the carotid body, as well as HT
(Del Rio et al., 2010), supporting the essential role of oxidative
stress in the generation of carotid body chemosensory potenti-
ation and systemic cardiorespiratory alterations induced by IH
(Del Rio et al., 2010).
More recently, Hung et al. tested the hypothesis that mela-
tonin, previously shown to ameliorate oxidative injury and
inflammation, could have a protective effect against IH-induced
HT and endothelial dysfunction. This assumption was confirmed
as melatonin promoted a decrease in systolic BP and prevented
endothelial dysfunction with ameliorated levels of nitric oxide,
endothelial-dependent relaxation, and expressions of eNOS and
antioxidant enzymes (Hung et al., 2013).
Based on the studies described, we can conclude that most
reports on CIH animal models in which drugs have been tested
were not designed to respond to pharmacological issues: they have
been used solely as pharmacological tools to address physiologi-
cal mechanisms. The experiments evaluate prevention but not the
effectiveness of treatment. They must be planned first to induce
HT and then evaluate the efficacy of cumulative doses of drugs
because the translation of the results to humans obtained with
simultaneous induction of HT and drug administration is not
relevant. Other limitations of the pharmacological approaches
included in these works are the absence of dose-response curves
and comparison of the effectiviness of different drugs in the same
animal model. Thus, other studies must be designed to overcome
these drawbacks.
WHAT ARE THE POTENTIAL NON-PHARMACOLOGICAL
APPROACHES TO THE MANAGEMENT OF HT RELATED TO
OSA?
Taken in perspective, the pathophysiology of HT related to OSA,
which involves an increase in sympathetic activity, renal dener-
vation seems to be a logical approach for patients with this type
of HT as renal sympathetic nerves are involved in the regula-
tion of BP. Indeed, the beneficial role of this novel approach in
the management of resistant HT and other cardiovascular dis-
eases has been reported and reviewed extensively (Grassi et al.,
2012; Pimenta and Oparil, 2012; Böhm et al., 2013; Ukena et al.,
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2013; Urban et al., 2013; Faselis et al., 2014; Tsioufis et al., 2014).
Moreover, Shantha and Pancholy (2014) have recently undertaken
a systematic review of the effect of renal sympathetic denervation
on AHI in patients with OSA. Curiously, they concluded that this
approach is associated with a significant reduction in mean AHI
(Shantha and Pancholy, 2014). However, as the authors pointed
out, these results need further validation due to the low causal
basis of the studies included in the analysis and due to the fact that
only one of these studies was performed fully in a specific popu-
lation of OSA patients; in the remaining studies, the diagnosis of
OSA was only established after inclusion (Shantha and Pancholy,
2014). In a recent pilot study, the effect of renal denervation
on BP control in patients with OSA was explored (Witkowski
et al., 2011). Despite the low causal basis (n = 10), their findings
demonstrated a significant BP decrease within 3 months, which
was further enhanced at 6 months, exhibiting a drop pattern sim-
ilar to clinical studies in resistant HT (Witkowski et al., 2011).
Nontheless, further studies are needed to support this impres-
sive effect of renal denervation and to ensure the safety of this
technique for patients with HT related to OSA.
Like renal denervation, carotid baroreceptor stimulation has
also been proposed as a novel AH therapy based on the recent
evidence that baroreceptors might play an important role even
in long-term BP regulation (Papademetriou et al., 2011; Grassi
et al., 2012; Lovic et al., 2014). The main similarities and differ-
ences between these two novel approaches have been reviewed
extensively by a group of Italian researchers (Grassi et al., 2014;
Seravalle et al., 2014). Although electrical baroreflex stimulation
appears to be safe and effective, and might represent a useful tool
for managing resistant HT (Lovic et al., 2014), to the best of our
knowledge, the effectiveness of this approach has not been yet
tested in models of IH. Thus, further investigation in this specific
field would be welcome.
In line with the pioneer study performed by Fletcher et al.
(1992c) that established that carotid body (CB) ablation elimi-
nated the hypertension related to CIH,McBryde et al. (2013) have
shown that CB deafferentation, through bilateral carotid sinus
nerve denervation, promotes an effective and lasting AH response
in SH rats and reduces the overactive sympathetic activity. They
have also demonstrated that associated with renal denervation,
carotid sinus nerve denervation remains effective and produces
a cumulative response (McBryde et al., 2013). In line with these
findings, they propose carotid sinus nerve denervation as an
effective AH treatment in patients with sympathetically mediated
diseases (McBryde et al., 2013).
More recently, Burchell et al. have reviewed the potential of a
new device for the control of arterial HT (Burchell et al., 2014).
The ROX coupler device creates an anastomosis between the
iliac artery and vein, diverting a calibrated amount of arterial
blood into the venous system, reducing vascular resistance and
increasing arterial compliance (Burchell et al., 2014). This non-
pharmacological approach seems to be a promising tool in the
management of patients with resistant HT due to its ability to pro-
vide an immediate and sustained reduction in BP (Burchell et al.,
2014). The safety and efficacy of the ROX coupler in the treatment
of this type of HT is now being evaluated in a European multi-
center randomized study (Burchell et al., 2014). Positive results in
www.frontiersin.org September 2014 | Volume 5 | Article 361 | 17
Diogo and Monteiro Antihypertensive drugs in CIH conditions
patients with drug-resistant HT leave open the possibility of the
use of the ROX coupler device becoming a new strategy for the
management of HT related to OSA.
CONCLUSIONS AND FUTURE PERSPECTIVES IN THE
MANAGEMENT OF HT RELATED TO OSA
There is consensus that HT related to OSA is gaining more
relevance as an independent nosological condition that needs
a systematic approach to identify the best therapeutic strategy.
One major challenge is gaining an understanding of whether the
blockade of the reflex pathways triggered by CB activation is suf-
ficiently effective to control BP in itself in HT related to OSA.
Eventually, other pathways directly stimulated by hypoxia at a cel-
lular level should be explored in depth and manipulated to attain
relevant clinical control of these patients.
Drugs that have proved to be useful in essential HT treat-
ment should be tested promptly in studies specifically designed
for secondary HT induced by CIH. On the other hand, given the
particularities of HT related to OSA, the recourse to tailored treat-
ments should be considered as a possibility. Furthermore, it also
appears to be imperative to look for new AHDs able to reverse HT
quickly and effectively in patients with OSA as BP control is still
not achievable in a significant proportion of these patients.
The contribution of animal models to this approach is unques-
tionable in terms of avoiding the confounding risk factors for HT
that tend to be present in OSA patients. In addition, drugs that
have been used as pharmacological tools to understand patho-
physological mechanisms should now be investigated regarding
their efficacy in reverting HT induced by CIH.
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